renewal are now highlighted as promising cell sources for regeneration medicine. Previously we demonstrated that mouse ES cell-derived vascular endothelial growth factor receptor-2 (VEGF-R2)-positive cells can differentiate into both endothelial cells and mural cells (pericytes and vascular smooth muscle cells) and reproduce the vascular organization process. 1 Vascular cells derived from VEGF-R2 ϩ cells can organize vessel-like structures in a 3-dimensional culture. Mouse ES cell-derived VEGF-R2 ϩ cells can, thus, serve as vascular progenitor cells (VPCs). Furthermore, we have reported that implantation of mouse ES-derived vascular cells into nude mice significantly augmented blood flow in an adult neoangiogenesis model, which suggests the usefulness of ES cell-derived VPCs for vascular regeneration medicine. 2 Recently primate embryonic stem cell lines were established from blastocysts of both humans and monkeys. [3] [4] [5] [6] Primate ES cells possess a number of characteristics distinct from mouse ES cells, such as surface antigens, leukemia inhibitory factor (LIF)-independence, and long doubling times. [3] [4] [5] [6] [7] Recent study showed that VEGF-R2 was expressed in undifferentiated human ES cells, unlike in mouse ES cells, 8, 9 and continuously expressed during differentiation in embryoid body (EB) formation. It has also been demonstrated that platelet endothelial cell adhesion molecule-1 (PECAM1)-positive cells can be isolated from human EBs, and they can act as endothelial cells. 9 However, the vascular differentiation process of primate cells has not been demonstrated, and VPCs that can differentiate into both endothelial cells and mural cells have not been characterized in the primates. To elucidate the vascular differentiation process of primate cells and to seek the clinical potential of VPCs for vascular regeneration therapy with the use of an in vitro 2-dimensional differentiation system of ES cells that we established, 10, 11 we examined whether and how VPCs occur in primate ES cells in comparison to mouse ES cells.
Methods

Cell Culture
Cynomolgus monkey ES cell lines were established, and their pluripotency was confirmed by teratoma formation in severe combined immunodeficiency mice, as described previously. 6, 12 Undifferentiated ES cells were maintained as described. 6, 12 OP9 feeder cell lines that were established from mouse calvaria were maintained as described previously. 11, 13, 14 To induce differentiation, undifferentiated ES cells were cultured on OP9 feeder layer in differentiation medium (minimal essential medium [GIBCO] supplemented with 10% fetal calf serum (FCS) and 5ϫ10 Ϫ5 M2-mercaptoethanol). 11 Sorted VEGF-R2 ϩ cells were re-cultured on an OP9 feeder layer or collagen IV-coated dish with differentiation medium. Three-dimensional culture was performed as described. 1
Flow Cytometry and Cell Sorting
At different time points during the differentiation process, cultured cells were harvested by cell dissociation buffer (GIBCO). Flow cytometry analysis and cell sorting were as discribed. 10, 11 Monoclonal antibody for VEGF-R2, which we developed, 15 was labeled with Alexa-647 in our laboratory (monoclonal antibody labeling kit, molecular probes). PE-conjugated vascular endothelial cadherin (VEcadherin) antibody and fluorescein isothiocyanate-conjugated PECAM1 antibody were purchased from BD Biosciences. To test the differentiation potential of VEGF-R2 ϩ cells, sorted cells were plated into a collagen IV-coated 96-well dish at the density of 2.5ϫ10 3 cells per well, or plated on OP9 feeder layer in a 24-well dish at 1ϫ10 4 cells per well.
Immunohistochemistry
Staining of culture cells on dishes was as described. 1, 11 Monoclonal antibody for smooth muscle actin (SMA) was purchased from Sigma, those for calponin and smooth muscle myosin heavy chain (SMMHC) were purchased from DAKO, and those for PECAM1, VEcadherin, and endothelial nitric oxide synthase (eNOS) were purchased from BD Biosciences.
Results
Although undifferentiated mouse ES cells did not express VEGF-R2, most of undifferentiated monkey ES cells were positive for VEGF-R2 (data not shown). Mouse ES cells differentiated into VEGF-R2 ϩ cells during a 4-day differentiation on OP9 feeder layer. These mouse VEGF-R2 ϩ cells differentiated into endothelial cells during 4 days of reculturing on a collagen IV-coated dish or OP9 feeder layer. 1, 11 In contrast, however, we could not induce endothelial cells from VEGF-R2 ϩ undifferentiated monkey ES cells in the same condition (data not shown). Thus, we examined VEGF-R2 expression on monkey ES cells during differentiation.
Undifferentiated monkey ES cells were dissociated to single cells and plated on an OP9 feeder layer to induce differentiation ( Figure 1A ). As shown in Figure 1B , VEGF-R2 was expressed in undifferentiated monkey ES cells (day 0), but disappeared during a 4-day differentiation on OP9 feeder layer, and then reappeared after 8 days of differentiation. VEcadherin ϩ cells appeared at day 10 of differentiation. Alkaline phosphatase activity, which was reported to be detected in undifferentiated ES cells 3, 5 but not in mature vascular cells, was clearly detected in undifferentiated ES cells but not in the cells that were cultured for 8 days on an OP9 feeder layer ( Figure 1C and 1D) , indicating that VEGF-R2 ϩ cells at 8-day differentiation are apparently distinct from those observed in undifferentiated ES cells.
VEGF-R2 ϩ VEcadherin Ϫ cells were purified by flow cytometry sorting at day 8 ( Figure 1A ). Additional 5-day culturing of VEGF-R2 ϩ VEcadherin Ϫ cells on an OP9 feeder layer resulted in the appearance of PECAM1 ϩ cells ( Figure  2A ), which were also positive for VEcadherin and eNOS ( Figure 2B and 2C ). On the other hand, on a collagen IV-coated dish with 10% FCS, more than 90% of VEGF-R2 ϩ VEcadherin Ϫ cells became positive for SMA ( Figure 2D ) and calponin ( Figure 2E) after an additional 5 days of culturing. Some were positive for SMMHC ( Figure 2F ). In this culturing condition, PECAM1 ϩ endothelial cells did not appear. In contrast, addition of 50ng/mL VEGF to culture on a collagen IV-coated dish resulted in the appearance of PECAM1 ϩ cells (about 20% of total cells) that were surrounded by SMA ϩ cells ( Figure 2G ). VEGF-R2 ϩ VEcadherin Ϫ cells at day 10 also could differentiate into endothelial cells and mural cells similarly to day 8. VEGF-R2 ϩ VEcadherin Ϫ cells doubled themselves in about 44 hours on a collagen IV-coated dish with VEGF and FCS. Almost all of the VEGF-R2 ϩ VEcadherin ϩ cells obtained by flow cytometry sorting at day 10 became positive for PECAM1 after an additional 5 days of culturing on a collagen IV-coated dish with 10% FCS.
We further examined whether VEGF-R2 ϩ cells can form vascular structure in vitro. Aggregates of several hundred VEGF-R2 ϩ cells were cultivated in collagen I-A gels with 10% FCS, 50ng/mL VEGF, 50ng/mL basic fibroblast growth factor, and 100 pM phorbol myristate acetate. The cells migrated out from the aggregates and formed cord-like structures within 3 days ( Figure 2H ).
Discussion
In the previous study, 1 we showed that VEGF-R2 ϩ cells in 4-day differentiation of mouse ES cells can differentiate into 2 major vascular cell types (endothelial cells and mural cells) in vitro and in vivo. Unlike mouse ES cells, undifferentiated monkey ES cells were already expressing VEGF-R2, similar to human ES cells. VEGF-R2 expression on monkey ES cells disappeared during 4-day differentiation on an OP9 feeder layer, and then re-expressed after 8 days of differentiation ( Figure 1C ). VEGF-R2-expressing cells on day 8 were different from VEGF-R2 ϩ undifferentiated monkey ES cells. First, the former did not show alkaline phosphatase activity as the latter did. Second, the former could differentiate into endothelial cells but the latter could not. Thus, the VEGF-R2 ϩ cells that re-appeared at 8 days of differentiation in monkey ES cell differentiation seem to possess similar differentiation potentials to those in 4-day differentiation of mouse ES cells, whereas VEGF-R2 expression in undifferentiated monkey ES cells should be of less functional significance in vascular differentiation.
In the present study, we demonstrated that VEGF-R2 ϩ VEcadherin Ϫ cells that appeared at 8-days' differentiation in monkey ES cells give rise to both endothelial cells and mural cells and form vascular-like structures in a 3-dimentional culture in vitro. Our findings indicate that differentiated VEGF-R2 ϩ cells can act as VPCs in primates, and the differentiation kinetics of VPCs in primate and mouse ES cells were different. Thus, to seek the clinical potential of VPCs for vascular regeneration and to obtain novel insights in primate vascular development, investigations of primate ES cells are indispensable. Our novel in vitro vascular differentiation system using VPCs derived from primate ES cells is promising for dissecting the molecular and cellular mechanisms in the primate vascular development, to which the knock-out animal research approach is not available.
